CRISPR Electroporation of T Cells Improves Treatment in Patients with Refractory Cancer

MaxCyte Puts A Focus On: Andrew Mancini, Field Applications Scientist

Andrew Mancini is a MaxCyte Field Applications Scientist, working closely with our partners around the world to develop novel cell engineering workflows for the development of cellular therapeutics. Having completed his PhD in Biomedical Sciences at the University of California, San Francisco and his postdoctoral training at Genentech in Molecular Oncology, Andrew has a broad range of experience and expertise that encompasses non-viral and viral engineering of primary immune cells, stem cells, and cell lines at both research and manufacturing scales. Let’s learn more!

Andrew, how do you best describe your position to our partners?

As a Field Applications Scientist at MaxCyte, I am the technical resource for any prospective or current customer looking to engineer cells using the MaxCyte electroporation platform, ranging from the initial technical support for instrument installations and training, to working closely with our customers to optimize their cell engineering processes at manufacturing scale. I collaborate with our partners every step of the process.

What would you say is your favorite part of working on the FAS team?

Honestly, I am inspired by the constant exposure to cutting-edge science that I get to see when working with our partners. I am unsure of any other position that allows you to see the direct translation of novel ideas from beginning concepts through to manufacturing.

In your opinion, what makes MaxCyte’s FAS team stand out from its competitors?

It is imperative that I provide a clear, direct line of communication to our partners, ensuring expectations are met and exceeded by being both proactive and transparent in communications, and leaving no room for confusion. It is also critical to be able to swiftly identify the key matter at hand. The quicker I can identify the true wants and needs of the customers, the quicker I can address them.

When it comes to customer service, what is your biggest priority?

Undoubtedly it is the level of support we provide to our partners, which is unparalleled in the biotechnology industry. Not only do we provide the standard support for instrument installation and training, which you would expect from any FAS team, but we pride ourselves on going above and beyond, offering direct support for a variety of areas including process development, tech transfer, experimental design, and even beyond the core cell engineering step all the way upstream and downstream in the customer’s process.

During your work on the FAS team, what are you most proud of?

Without a doubt, I am most proud of the progress we have made, and continue to make, in furthering novel cellular therapeutics into the clinic. Being an integral part of the drug development process for first-in-class cell therapies allows me to contribute to something bigger, something where we truly make a difference in patient lives. The work is humbling, inspiring and impactful – how could I not be proud of that!

Andrew, thank you for the time, and your incredible commitment to your position, our partners and the advancement of cell therapy.

Return to MaxCyte Minutes Newsletter